Filtered By:
Cancer: Leukemia
This page shows you your search results in order of date. This is page number 8.
Order by Relevance | Date
Total 28070 results found since Jan 2013.
Association of < em > CYP3A5*3, CYP3A4*18 & amp; CYP2B6*6 < /em > polymorphisms with imatinib treatment outcome in Azerbaijani chronic myeloid leukaemia patients
CONCLUSIONS: Our results demonstrated that CYP3A4*18 was significantly associated with IM treatment response in patients with CML in Azerbaijan, whereas rather common CYP3A5*3 was identified to have no such association.PMID:37706370 | DOI:10.4103/ijmr.ijmr_1103_22
Source: Indian J Med Res - September 14, 2023 Category: Research Authors: Chingiz Asadov Nigar Karimova Aypara Hasanova Bayram Bayramov Aytan Shirinova Zohra Alimirzoyeva Source Type: research
Myeloid sarcoma and pathological fracture: a case report and review of literature
Int J Hematol. 2023 Sep 14. doi: 10.1007/s12185-023-03656-1. Online ahead of print.ABSTRACTMyeloid sarcoma is a rare clinical entity that presents as an isolated proliferation of leukemic cells, concurrently with or at relapse of acute myeloid leukemia (AML), myelodysplastic syndromes/neoplasms (MDS), chronic myeloid leukemia (CML), and myeloproliferative neoplasm (MPN). Myeloid sarcoma disrupts the normal architecture of its surrounding tissues. When it forms in long bones, it can cause their pathological fracture. We recently experienced a rare case of MDS presenting with myeloid sarcoma in the femur that eventually resu...
Source: International Journal of Hematology - September 14, 2023 Category: Hematology Authors: Sho Takeyasu Ken Morita Seitaro Saito Masanori Toho Takashi Oyama Takafumi Obo Kazuki Taoka Arika Shimura Hiroaki Maki Eisuke Shibata Yusuke Watanabe Fumio Suzuki Liuzhe Zhang Hiroshi Kobayashi Munetoshi Hinata Mineo Kurokawa Source Type: research
Association of < em > CYP3A5*3, CYP3A4*18 & amp; CYP2B6*6 < /em > polymorphisms with imatinib treatment outcome in Azerbaijani chronic myeloid leukaemia patients
CONCLUSIONS: Our results demonstrated that CYP3A4*18 was significantly associated with IM treatment response in patients with CML in Azerbaijan, whereas rather common CYP3A5*3 was identified to have no such association.PMID:37706370 | DOI:10.4103/ijmr.ijmr_1103_22
Source: The Indian Journal of Medical Research - September 14, 2023 Category: Biomedical Science Authors: Chingiz Asadov Nigar Karimova Aypara Hasanova Bayram Bayramov Aytan Shirinova Zohra Alimirzoyeva Source Type: research
Myeloid sarcoma and pathological fracture: a case report and review of literature
Int J Hematol. 2023 Sep 14. doi: 10.1007/s12185-023-03656-1. Online ahead of print.ABSTRACTMyeloid sarcoma is a rare clinical entity that presents as an isolated proliferation of leukemic cells, concurrently with or at relapse of acute myeloid leukemia (AML), myelodysplastic syndromes/neoplasms (MDS), chronic myeloid leukemia (CML), and myeloproliferative neoplasm (MPN). Myeloid sarcoma disrupts the normal architecture of its surrounding tissues. When it forms in long bones, it can cause their pathological fracture. We recently experienced a rare case of MDS presenting with myeloid sarcoma in the femur that eventually resu...
Source: International Journal of Hematology - September 14, 2023 Category: Hematology Authors: Sho Takeyasu Ken Morita Seitaro Saito Masanori Toho Takashi Oyama Takafumi Obo Kazuki Taoka Arika Shimura Hiroaki Maki Eisuke Shibata Yusuke Watanabe Fumio Suzuki Liuzhe Zhang Hiroshi Kobayashi Munetoshi Hinata Mineo Kurokawa Source Type: research
Ultra-deep mutational landscape in chronic lymphocytic leukemia uncovers dynamics of resistance to targeted therapies
Haematologica. 2023 Sep 14. doi: 10.3324/haematol.2023.283372. Online ahead of print.ABSTRACTBTK inhibitors, Bcl-2 inhibitors, and other targeted therapies have significantly improved outcomes for patients with chronic lymphocytic leukemia (CLL). With increased survivorship, monitoring disease and deciphering potential mechanisms of resistance to these agents are critical for devising effective treatment strategies. We used duplex sequencing, a technology that enables detection of mutations at ultra-low allelic frequencies, to identify mutations in five genes associated with drug resistance in CLL and followed their evolut...
Source: Haematologica - September 14, 2023 Category: Hematology Authors: David W Woolston Nathan D Lee Mazyar Shadman Elena Latorre-Esteves Xin Ray Tee Jeanne Fredrickson Brendan F Kohrn Chaitra Ujjani Ashley Eckel Brian Till Min Fang Jerald Radich Ivana Bozic Rosa Ana Risques Cecilia C S Yeung Source Type: research
Prognostic value of European Leukemia Net 2022 criteria and genomic clusters using machine learning in older adults with acute myeloid leukemia
This study aimed to validate the new European Leukemia Net (ELN) 2022 criteria for genetic risk stratification in older adults with acute myeloid leukemia (AML) and to determine the most likely set of clusters of similar cytogenetic and mutation properties correlated with survival outcomes in three treatment groups: intensive chemotherapy (IC), hypomethylating agents (HMAs) alone, and HMAs plus venetoclax (HMA/VEN). The study included 279 patients (≥60 years) who received IC (n=131), HMA (n=76), and HMA/VEN (n=72) between July 2017 and October 2021. No significant differences were observed in survival among the groups ac...
Source: Haematologica - September 14, 2023 Category: Hematology Authors: Silvia Park Tong Yoon Kim Byung-Sik Cho Daehun Kwag Jong-Mi Lee MyungShin Kim Yonggoo Kim Jamin Koo Anjali Raman Tae Kon Kim Hee-Je Kim Source Type: research
Somatic variant profiling in chronic phase pediatric chronic myeloid leukemia
Haematologica. 2023 Sep 14. doi: 10.3324/haematol.2023.283800. Online ahead of print.ABSTRACTNot available.PMID:37706343 | DOI:10.3324/haematol.2023.283800
Source: Haematologica - September 14, 2023 Category: Hematology Authors: Yvonne Lisa Behrens Laura Gaschler Ronny Nienhold Thea Reinkens Elke Schirmer Sabine Kn öß Renate Strasser Stephanie Sembill Zofia Wotschofsky Meinolf Suttorp Manuela Krumbholz Brigitte Schlegelberger Markus Metzler Gudrun G öhring Axel Karow Source Type: research
Daratumumab and brentuximab vedotin combination therapy in T-cell acute lymphoblastic leukemia refractory to conventional chemotherapy and allogeneic stem cell transplant
Haematologica. 2023 Sep 14. doi: 10.3324/haematol.2023.283740. Online ahead of print.ABSTRACTNot available.PMID:37706335 | DOI:10.3324/haematol.2023.283740
Source: Haematologica - September 14, 2023 Category: Hematology Authors: Kebede H Begna Nadine H Abdallah Michelle Janania-Martinez Abhishek A Mangaonkar Aruna Rangan Jennifer L Herrick Naseema Gangat Source Type: research
Ultra-deep mutational landscape in chronic lymphocytic leukemia uncovers dynamics of resistance to targeted therapies
Haematologica. 2023 Sep 14. doi: 10.3324/haematol.2023.283372. Online ahead of print.ABSTRACTBTK inhibitors, Bcl-2 inhibitors, and other targeted therapies have significantly improved outcomes for patients with chronic lymphocytic leukemia (CLL). With increased survivorship, monitoring disease and deciphering potential mechanisms of resistance to these agents are critical for devising effective treatment strategies. We used duplex sequencing, a technology that enables detection of mutations at ultra-low allelic frequencies, to identify mutations in five genes associated with drug resistance in CLL and followed their evolut...
Source: Haematologica - September 14, 2023 Category: Hematology Authors: David W Woolston Nathan D Lee Mazyar Shadman Elena Latorre-Esteves Xin Ray Tee Jeanne Fredrickson Brendan F Kohrn Chaitra Ujjani Ashley Eckel Brian Till Min Fang Jerald Radich Ivana Bozic Rosa Ana Risques Cecilia C S Yeung Source Type: research
Prognostic value of European Leukemia Net 2022 criteria and genomic clusters using machine learning in older adults with acute myeloid leukemia
This study aimed to validate the new European Leukemia Net (ELN) 2022 criteria for genetic risk stratification in older adults with acute myeloid leukemia (AML) and to determine the most likely set of clusters of similar cytogenetic and mutation properties correlated with survival outcomes in three treatment groups: intensive chemotherapy (IC), hypomethylating agents (HMAs) alone, and HMAs plus venetoclax (HMA/VEN). The study included 279 patients (≥60 years) who received IC (n=131), HMA (n=76), and HMA/VEN (n=72) between July 2017 and October 2021. No significant differences were observed in survival among the groups ac...
Source: Haematologica - September 14, 2023 Category: Hematology Authors: Silvia Park Tong Yoon Kim Byung-Sik Cho Daehun Kwag Jong-Mi Lee MyungShin Kim Yonggoo Kim Jamin Koo Anjali Raman Tae Kon Kim Hee-Je Kim Source Type: research
Somatic variant profiling in chronic phase pediatric chronic myeloid leukemia
Haematologica. 2023 Sep 14. doi: 10.3324/haematol.2023.283800. Online ahead of print.ABSTRACTNot available.PMID:37706343 | DOI:10.3324/haematol.2023.283800
Source: Haematologica - September 14, 2023 Category: Hematology Authors: Yvonne Lisa Behrens Laura Gaschler Ronny Nienhold Thea Reinkens Elke Schirmer Sabine Kn öß Renate Strasser Stephanie Sembill Zofia Wotschofsky Meinolf Suttorp Manuela Krumbholz Brigitte Schlegelberger Markus Metzler Gudrun G öhring Axel Karow Source Type: research
Daratumumab and brentuximab vedotin combination therapy in T-cell acute lymphoblastic leukemia refractory to conventional chemotherapy and allogeneic stem cell transplant
Haematologica. 2023 Sep 14. doi: 10.3324/haematol.2023.283740. Online ahead of print.ABSTRACTNot available.PMID:37706335 | DOI:10.3324/haematol.2023.283740
Source: Haematologica - September 14, 2023 Category: Hematology Authors: Kebede H Begna Nadine H Abdallah Michelle Janania-Martinez Abhishek A Mangaonkar Aruna Rangan Jennifer L Herrick Naseema Gangat Source Type: research
Association of < em > CYP3A5*3, CYP3A4*18 & amp; CYP2B6*6 < /em > polymorphisms with imatinib treatment outcome in Azerbaijani chronic myeloid leukaemia patients
CONCLUSIONS: Our results demonstrated that CYP3A4*18 was significantly associated with IM treatment response in patients with CML in Azerbaijan, whereas rather common CYP3A5*3 was identified to have no such association.PMID:37706370 | DOI:10.4103/ijmr.ijmr_1103_22
Source: The Indian Journal of Medical Research - September 14, 2023 Category: Biomedical Science Authors: Chingiz Asadov Nigar Karimova Aypara Hasanova Bayram Bayramov Aytan Shirinova Zohra Alimirzoyeva Source Type: research
Cladribine, Cytarabine, And Etoposide (CCE)-Based Regimens Are Safe and Tolerable In Relapsed And Refractory AML Patients
Acta Haematol. 2023 Sep 14. doi: 10.1159/000534024. Online ahead of print.ABSTRACTIntensive treatment regimens for relapsed/refractory (R/R) acute myeloid leukemia (AML) generally include an anthracycline, cytarabine, with or without a purine analogue. In patients who cannot tolerate an anthracycline due to comorbidities may consider using etoposide. Given the ongoing fludarabine shortage, it has prompted the switch to other purine analogues, such as cladribine, in combination with cytarabine and etoposide in patients who may be eligible for intensive chemotherapy but not able to tolerate an anthracycline due to comorbidit...
Source: Acta Haematologica - September 14, 2023 Category: Hematology Authors: Jose Tinajero Dat Ngo Amandeep Salhotra Paul Koller Source Type: research
